Transpara vs Koios DS for Breast

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Transpara

by ScreenPoint Medical

Koios DS for Breast

by Koios Medical

AI Verdict

Transpara and Koios DS for Breast are both FDA-cleared AI solutions designed to aid in breast cancer detection and optimize radiologist workflow. However, Transpara focuses on 2D and 3D mammography, including temporal comparison and breast density assessment, while Koios DS for Breast specializes in analyzing ultrasound images and classifying breast lesions into BI-RADS or U1-U5 categories. Therefore, they are adjacent competitors, serving similar goals but utilizing different imaging modalities.

Choose Transpara if…

Choose Transpara if your facility primarily focuses on enhancing breast cancer detection and optimizing workflow for 2D and 3D mammography. It is particularly well-suited for high-volume screening programs, offering features like temporal comparison and risk categorization to aid radiologists in efficiently identifying subtle signs of cancer and reducing workload.

View Transpara →

Choose Koios DS for Breast if…

Choose Koios DS for Breast if your practice specializes in breast ultrasound and aims to improve the accuracy of breast cancer diagnosis from ultrasound images. This tool excels at classifying breast lesions into BI-RADS or European U1-U5 categories and providing AI-derived cancer risk assessments, which can significantly reduce unnecessary biopsies and enhance diagnostic confidence.

View Koios DS for Breast →

When choosing between Transpara and Koios DS for Breast, physicians should consider the primary imaging modality they utilize for breast cancer screening and diagnosis. Transpara, developed by ScreenPoint Medical, is specifically designed to enhance breast cancer detection and optimize workflow for 2D and 3D mammography. Its key features include AI-powered detection for both FFDM and DBT, temporal comparison capabilities, breast density assessment, and risk categorization. This tool is best suited for practices heavily reliant on mammography, aiming for earlier detection and improved efficiency in their mammography reading workflow.

In contrast, Koios DS for Breast from Koios Medical focuses on providing AI-powered clinical decision support for radiologists analyzing ultrasound images. It aids in classifying breast lesions into ACR BI-RADS or European U1-U5 categories, generates cancer risk assessments, and offers lexicon-based descriptors. The practical difference lies in their core application: Transpara is a mammography-centric AI, while Koios DS for Breast is an ultrasound-centric AI. Therefore, a physician whose practice primarily utilizes mammography for screening and diagnosis would find Transpara more aligned with their needs, while a physician heavily involved in breast ultrasound interpretation would benefit more from Koios DS for Breast.

Quick Comparison

Feature	Transpara	Koios DS for Breast
Pricing	Unknown	Subscription
Deployment	Transpara integrates into PACS and reading workflows via medical-imaging (DICOM) pipelines. It is also available through Precision Imaging Network, part of Microsoft for Healthcare, which simplifies deployment pathways for cloud-enabled access within existing clinical ecosystems.	On-premise (PACS integrated), Cloud (via partners)
FDA Status	Cleared AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both Transpara and Koios DS for Breast emphasize seamless integration into existing PACS and reading workflows, aiming to enhance efficiency and reduce workload for radiologists. Both claim intuitive interfaces and rapid deployment, suggesting a comparable focus on user experience.

Clinical Value

Transpara

Transpara has a strong body of clinical evidence, including being the first and only breast AI to be studied in a randomized controlled trial (MASAI trial), which reported a 29% increase in cancer detection and a 44% workload reduction. While Koios DS for Breast also has studies demonstrating improved diagnostic accuracy and reduced benign biopsies, Transpara's evidence base appears more extensive and rigorous with large-scale randomized controlled trials.

Pricing & Value

Tie

Koios DS for Breast states annual subscription pricing tailored to customer size, based on the number of analyses and/or users. Transpara's pricing information is not explicitly detailed in the provided data, but its documentation mentions subscription plans and transparency. Without specific pricing details for Transpara, a direct comparison of value is not possible.

Enterprise Readiness

Transpara

Transpara is deployed in over 30 countries and has analyzed over 13 million mammograms, indicating a robust and scalable solution for large health systems and screening programs. Its integration with Microsoft for Healthcare's Precision Imaging Network further highlights its enterprise capabilities. Koios DS for Breast also offers on-premise and cloud deployment and PACS integration, but its scale of deployment and customer count are not as extensively detailed.

Innovation

Transpara

Transpara offers advanced features like temporal comparison, analyzing current studies against up to three prior exams over six years, and provides both BI-RADS-like and volumetric breast density assessments. While Koios DS for Breast utilizes AI/ML for classifying lesions and risk assessment, Transpara's temporal comparison and extensive mammography capabilities suggest a broader scope of innovative features for breast cancer detection.

Support & Docs

Transpara

Transpara explicitly mentions comprehensive support including documentation, a knowledge base, online training, and proactive support with frequent software updates. Koios DS for Breast mentions a user guide and contact information for support, but the breadth and depth of its support resources are not as clearly articulated as Transpara's.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Transpara	Koios DS for Breast
Name	Transpara	Koios DS for Breast
Company	ScreenPoint Medical	Koios Medical
Primary Imaging Modality	2D and 3D mammography (FFDM and DBT)	Ultrasound images
Key Feature: Breast Density Assessment	Breast Density assessment (BI-RADS-like and volumetric)	Not specified
Key Feature: Risk Categorization	Risk categorization (Elevated, Intermediate, Low)	Generates AI/ML-derived cancer risk assessment
Key Feature: Temporal Comparison	Temporal Comparison (analyzes current study against up to 3 priors over 6 years)	Not specified
Key Feature: BI-RADS Classification	Not specified	Classifies breast lesions into ACR BI-RADS or European U1-U5 categories
Customer Count/Usage	Deployed in over 30 countries, used to analyze over 13 million mammograms worldwide, used in over 200 clinics in 25+ countries	Not specified

Videos

Demos, reviews, and walkthroughs featuring Transpara and Koios DS for Breast.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing radiology workflows and EHR systems?

Transpara integrates into PACS and reading workflows via medical-imaging (DICOM) pipelines and is also available through the Precision Imaging Network for cloud-enabled access within existing clinical ecosystems. Koios DS for Breast offers seamless PACS integration and provides an image viewer for multi-modality digital images, including ultrasound and mammography, along with tools for structured reporting.

What is the primary imaging modality each tool supports and what are their respective strengths in accuracy and sensitivity for breast cancer detection?

Transpara specializes in AI-powered detection for 2D and 3D mammograms (FFDM and DBT), offering a high negative predictive value of 99.97% for low-risk cases. Koios DS for Breast primarily aids in the analysis of ultrasound images, classifying breast lesions into ACR BI-RADS or European U1-U5 categories and generating AI/ML-derived cancer risk assessments.

Given our multi-site practice, what are the key considerations for rolling out either of these AI solutions across different locations?

Transpara's deployment via DICOM pipelines and cloud-enabled access through the Precision Imaging Network suggests flexibility for multi-site rollouts. Koios DS for Breast offers both on-premise (PACS integrated) and cloud deployment options, which could be a factor in multi-site implementation depending on existing infrastructure and preferences.

What kind of audit-trail features do these tools offer to ensure transparency and accountability in AI-assisted diagnoses?

While specific audit-trail features are not detailed, both tools are clinical decision support systems. Transpara provides region-based and overall exam scores, and Koios DS for Breast offers lexicon-based descriptors and structured reporting tools, which inherently contribute to documentation and an audit trail of the AI's input into the diagnostic process.

How do these tools contribute to workload reduction and workflow optimization for radiologists?

Transpara is designed for workflow optimization and workload reduction, acting as a concurrent reading aid for radiologists. Koios DS for Breast aims to improve workflow efficiency by assisting radiologists in the early and accurate diagnosis of breast cancer from ultrasound images.

What kind of support and training can we expect to ensure our team can effectively utilize these tools?

While specific details on support and training are not provided, both companies offer sophisticated AI solutions for medical imaging. Given their target audience of hospitals, radiology practices, and health systems, it is reasonable to expect comprehensive support and training programs to facilitate effective utilization and integration into clinical practice.

Can these tools assist with temporal comparison or multi-modality image viewing to enhance diagnostic confidence?

Transpara offers Temporal Comparison, analyzing the current study against up to three prior studies over six years. Koios DS for Breast provides an image viewer for multi-modality digital images, including ultrasound and mammography, which can aid in a comprehensive review.